Interferonfreie Therapie der Hepatitis C – wie und wann wird sie Realität?

Schlüsselwörter

Hepatitis C - interferonfreie Therapie - direkte antivirale Substanzen - Proteaseinhibitoren (PI) - nukleos(t)idische Inhibitoren (NI) - NS5A-Inhibitoren

Keywords

hepatitis C - interferon-free therapy - directly acting antiviral agents - protease inhibitors (PI) - nucleos(t)idic inhibitors - NS5A inhibitors

• Literatur

• 1 Chayama K, Takahashi S, Toyota J et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor asunaprevir in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-748
• 2 Everson G, Sims K, Rodriguez-Torres M et al. An interferon-free, ribavirin-free 12-week regimen of daclastavir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection. AASLD 2012; LB–3
• 3 Feld J, Jacobson IM, Jensen D et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/- peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. AASLD 2012; 81A
• 4 Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C Infection. N Engl J Med 2013; 368: 1878-1887
• 5 Gane E, Roberts SK, Stedman C et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1). Lancet 2010; 376: 1467-1475
• 6 Gane E, Stedman C, Hyland R et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44
• 7 Gane E, Stedman C, Hyland R et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with genotypes 1,2, and 3: the ELECTRON trial. AASLD 2012; 56: 229A. 10
• 8 Gane EJ, Pockros P, Zeuzem S et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without RBV in treatment naïve HCV genotype 1 infected patients. EASL 2012; 1412A
• 9 Gilead. Gilead announces early sustained virologic response rates for GS-7977 plus ribavirin in genotype 1 treatment naïve hepatitis C patients. http://www.gilead.com/pr_1684792 (letzter Zugriff 16.04.2013)
• 10 Gilead. Gilead announces sustained virologic response rate of 78% from phase 3 study of sofosbuvir for genotype 2/3 hepatitis C infected patients. www.gilead.com/pr_1761988 (letzter Zugriff 15.04.2013)
• 11 Jacobson IM, Sulkowski MS, Gane E et al. VX-222, Telaprevir and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen. AASLD 2012; 231A
• 12 Kowdley KV, Lawitz E, Poordad F et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin achieves SVR12 rates (observed data) of 99% in treatment naive patients and 93% in prior null responders with HCV genotype 1 infection. AASLD 2012; LB1
• 13 Kronenberger B, Zeuzem S. Antiviral targets in HCV. In: Shiffman ML, ed. Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future. 1st ed. New York: Springer; 2012: 203-221
• 14 Lawitz E, Ghalib R, Rodriguez-Torres M et al. Suppression of viral load through 4 weeks post-treatment. Results of a once-daily regimen of simeprevir + sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null responders. CROI 2013; LB115A
• 15 Lok AS, Gardiner D, Hezode C et al. Sustained virologic response in chronic HCV genotype (GT)1-infected null responders with combination of daclastavir (DCV; NS5A Inhibitor) and asunaprevir (ASV; NS3 Inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). AASLD 2012; 79A
• 16 Lok AS, Gardiner D, Lawitz E et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224
• 17 Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without treatment options. N Engl J Med 2013; 368: 1867-1877
• 18 Osinusi A, Bon D, Herrmann E et al. High efficacy of sofosbuvir with weight-based ribavirin for 24 weeks in difficult-to-treat patients. CROI 2013; LB157A
• 19 Poordad F, Lawitz E, Kowdley KV et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53
• 20 Sarrazin C, Berg T, Cornberg M et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C. Z Gastroenterol 2012; 50: 57-72
• 21 Sarrazin C, Hézode C, Zeuzem S et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56S: 88-100
• 22 Soriano V, Gane E, Angus PW et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335+BI 207127 +/- ribavirin (RBV) in treatment-naive patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: results from the SOUND-C2 study. AASLD 2012; 84A
• 23 Sulkowski M, Gardiner D, Rodriguez-Torres M et al. High rate of sustained virologic response with the all-oral combination of daclastavir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment naive patients chronically infected with HCV genotype 1, 2, 3. AASLD 2012; LB2A
• 24 Sulkowski MS, Rodriguez-Torres M, Lawitz E et al. Complete SVR4 rates in treatment-naïve HCV genotype 1a and 1b patients who achieved vRVR with an interferon-free all-oral regimen. AASLD 2012; 212A
• 25 Suzuki Y, Ikeda K, Suzuki F et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-662
• 26 Toyota J, Ozeki I, Karino Y et al. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat 2013; 20: 167-173
• 27 Zeuzem S, Soriano V, Asselah T et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639